Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$55.89 - $101.89 $174,376 - $317,896
-3,120 Reduced 59.37%
2,135 $209,000
Q4 2020

Feb 16, 2021

SELL
$110.06 - $133.7 $264,144 - $320,880
-2,400 Reduced 31.35%
5,255 $584,000
Q1 2020

May 12, 2020

BUY
$66.76 - $93.49 $13,552 - $18,978
203 Added 2.72%
7,655 $511,000
Q3 2019

Nov 12, 2019

BUY
$84.4 - $106.53 $7,005 - $8,841
83 Added 1.13%
7,452 $648,000
Q2 2019

Aug 06, 2019

BUY
$91.13 - $142.5 $32,442 - $50,730
356 Added 5.08%
7,369 $772,000
Q1 2019

May 15, 2019

BUY
$103.48 - $143.84 $236,555 - $328,818
2,286 Added 48.36%
7,013 $878,000
Q4 2018

Feb 11, 2019

SELL
$94.77 - $215.54 $1,232 - $2,802
-13 Reduced 0.27%
4,727 $533,000
Q3 2018

Nov 13, 2018

BUY
$207.3 - $300.31 $982,602 - $1.42 Million
4,740 New
4,740 $1.02 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.17B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Altshuler Shaham LTD Portfolio

Follow Altshuler Shaham LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altshuler Shaham LTD, based on Form 13F filings with the SEC.

News

Stay updated on Altshuler Shaham LTD with notifications on news.